What is the Gyre Therapeutics Inc. stock price forecast?

Gyre Therapeutics Inc. is currently trading at $5.82. View real-time AI analysis on Alpha Lenz.

What is Gyre Therapeutics Inc. insider trading activity?

View the latest insider trading data for Gyre Therapeutics Inc. on Alpha Lenz.

What is Gyre Therapeutics Inc.'s P/E ratio?

Gyre Therapeutics Inc.'s P/E ratio is 103.4.

Gyre Therapeutics Inc.

NASDAQ · GYRE

$5.82-0.04(-0.68%)Pre-market

Ask about Gyre Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Gyre Therapeutics Inc. trades at a P/E of 103.4 (premium valuation) with modest ROE of 5.9%. 3Y revenue CAGR of 102.5% highlights clear growth momentum.”

Ask for details →

Company Overview

Gyre Therapeutics Inc. is a biotechnology firm dedicated to the discovery and development of innovative therapies for unmet medical needs. Its primary function is to leverage cutting-edge research and development technologies to address complex diseases and conditions that currently lack effective treatments. Gyre Therapeutics operates within the healthcare and biomedical sectors, impacting areas such as oncology, neurology, and rare genetic disorders. The company employs a robust pipeline strategy, focusing on both in-house R&D and collaborative partnerships to accelerate drug development and facilitate clinical trials. Through strategic alliances with academic institutions and pharmaceutical companies, Gyre Therapeutics aims to enhance its scientific capabilities and expand its therapeutic portfolio. As a specialized entity in the biotech industry, Gyre Therapeutics plays a crucial role in advancing medical science, potentially transforming patient care by bringing novel bio-pharmaceutical products to the market.

CEODr. Han Ying Ph.D.

Websitehttps://www.gyretx.com

SectorHealthcare

IndustryBiotechnology

Employees579

Company Statistics

FY 2025

Profile

$519.99MMarket Cap

$116.59MRevenue

0.00Shares Out

579Employees

Margins

95.35%Gross

9.70%EBITDA

9.86%Operating

12.38%Pre-Tax

8.47%Net

Valuation

103.44P/E

4.90P/B

4.46EV/Sales

45.99EV/EBITDA

-569.54P/FCF

Growth (CAGR)

102.48%Rev 3Yr

N/ARev 5Yr

108.73%Op Inc 3Yr

N/AOp Inc 5Yr

155.51%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

6.78%ROA

5.94%ROE

7.88%ROIC

Financial Health

$37.07MCash & Cash Equivalents

$-13.22MNet Debt

16.76%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Gyre Therapeutics Inc. trades at a P/E of 103.4 (premium valuation) with modest ROE of 5.9%. 3Y revenue CAGR of 102.5% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Gyre Therapeutics Inc. (ticker: GYRE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 579 employees. Market cap is $520M.

The current price is $5.82 with a P/E ratio of 103.44x and P/B of 4.9x.

ROE is 5.94% and operating margin is 9.86%. Annual revenue is $117M.